Sign Up to like & get
recommendations!
0
Published in 2019 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2018.11.023
Abstract: Osteomyelitis remains difficult to treat, typically requiring a prolonged course of intravenous (i.v.) antibiotics. The optimal route and duration of antibiotics remains ill-defined due to limited prospective clinical trials. Oritavancin is a long-acting, semisynthetic lipoglycopeptide…
read more here.
Keywords:
chronic osteomyelitis;
osteomyelitis multidose;
multidose oritavancin;
treatment chronic ... See more keywords